Drug Profile


Alternative Names: 3 DG; CI 908; Deazaguanine; ICN 4221; NSC 261726; Oncozole; PD 9069573

Latest Information Update: 28 Nov 2000

Price : $50

At a glance

  • Originator Viratek
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Nov 2000 No-Development-Reported for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top